Other Highlights in the July 3 Issue of JNCI

Compound Delays Progression of Premalignant Lung Lesions:
A phase IIb study of anethole dithiolethione (ADT) in smokers with bronchial dysplasia (pre-malignant lesions in the lung) suggests that the compound is an effective chemopreventive strategy for lung cancer control. These findings appear in the July 3 issue of the Journal of the National Cancer Institute.

ADT is one of two organosulfur compounds that are being studied for their ability to stimulate the production of enzymes that detoxify carcinogens. ADT has been approved in Canada and Europe for the treatment of drug- and radiation-induced dryness of the mouth and other conditions. To examine the effectiveness of ADT as a chemopreventive agent in lung cancer, Stephen Lam, M.D., of the British Columbia Cancer Agency and the University of British Columbia, and his colleagues randomly assigned 112 current and former smokers with bronchial dysplasia to receive either ADT or a placebo for 6 months.

Compared with patients who received placebo, those who received ADT had a lower rate of progression by two or more grades of preexisting dysplastic lesions and a reduction in the appearance of new lesions. Side effects of ADT were minor and included gastrointestinal symptoms that subsided after dose reduction or completion of ADT treatment.

Vitamin B12 May be Effective Carrier of Anticancer Drug:
Vitamin B12, an essential micronutrient, is required by tumors in increased concentrations compared with normal tissue. Joseph A. Bauer, Ph.D., and Daniel J. Lindler, M.D., Ph.D., of the Cleveland Clinic Foundation, and their colleagues examined whether a vitamin B12 analogue could be used as a carrier molecule to direct a chemotherapy drug to tumor cells.

The authors attached nitric oxide, which is toxic when internalized by cells, to vitamin B12. When mice bearing human tumors were treated with this compound, the tumors regressed. However, when the mice

Contact: Linda Wang
Journal of the National Cancer Institute

Page: 1 2 3

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 19 JNCI
8. Other highlights in the May 5 JNCI
9. Other highlights of the March 17 issue of JNCI
10. Other highlights in the March 3 issue of JNCI
11. Other highlights in the February 18 issue of JNCI

Post Your Comments:

(Date:6/23/2017)... N.Y. , June 23, 2017  IBM (NYSE: ... dairy research, today announced a new collaboration using next-generation ... chances that the global milk supply is impacted by ... Cornell University has become the newest academic institution to ... a food safety initiative that includes IBM Research, Mars, ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® test, ... clinically significant acute bacterial and viral respiratory tract infections by testing the ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
Breaking Biology Technology:
Cached News: